GTSFX
Price
$43.81
Change
+$0.36 (+0.83%)
Updated
Aug 21 closing price
Net Assets
1.59B
VEXRX
Price
$126.53
Change
+$0.81 (+0.64%)
Updated
Aug 21 closing price
Net Assets
22.12B
Interact to see
Advertisement

GTSFX vs VEXRX

GTSFX vs VEXRX Comparison Chart in %
View a ticker or compare two or three
VS
GTSFX vs. VEXRX commentary
Aug 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GTSFX is a Hold and VEXRX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VEXRX has more cash in the bank: 22.1B vs. GTSFX (1.59B). VEXRX pays higher dividends than GTSFX: VEXRX (0.49) vs GTSFX (0.00). GTSFX was incepted earlier than VEXRX: GTSFX (14 years) vs VEXRX (25 years). GTSFX (0.76) is less costly to investors than VEXRX (0.28). GTSFX is a more actively managed with annual turnover of: 85.00 vs. VEXRX (51.00). VEXRX has a lower initial minimum investment than GTSFX: VEXRX (50000) vs GTSFX (1000000). VEXRX annual gain was more profitable for investors over the last year : 17.56 vs. GTSFX (13.20). VEXRX return over 5 years is better than : -5.23 vs. GTSFX (-27.98).
GTSFXVEXRXGTSFX / VEXRX
Total Expense Ratio0.760.28271%
Annual Report Gross Expense Ratio0.760.28271%
Fund Existence14 years25 years-
Gain YTD14.08918.59676%
Front LoadN/AN/A-
Min. Initial Investment1000000500002,000%
Min. Initial Investment IRAN/AN/A-
Net Assets1.59B22.1B7%
Annual Yield % from dividends0.000.49-
Returns for 1 year13.2017.5675%
Returns for 3 years41.6034.85119%
Returns for 5 years-27.98-5.23535%
Returns for 10 years14.6055.0427%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
THPMX17.600.14
+0.80%
Thompson MidCap
AIVBX22.210.17
+0.77%
American Funds Intl Vntg A
GSSUX45.930.22
+0.48%
Goldman Sachs Small Cap Value R6
TSNIX70.000.19
+0.27%
T. Rowe Price Science & Tech I
JMNAX14.04-0.01
-0.07%
JPMorgan Research Market Neutral A